Safety and tolerability of tedizolid as oral treatment for bone and joint infections

By sjmartinez • September 27, 2023

Miller LG, Flores EA, Launer B, Lee P, Kalkat P, Derrah K, Agrawal S, Schwartz M, Steele G, Kim T, Kuvhenguhwa MS. Safety and tolerability of tedizolid as oral treatment for bone and joint infections. Microbiol Spectr. 2023 Sep 26:e0128223. doi: 10.1128/spectrum.01282-23. Epub ahead of print. PMID: 37750695.

Tags: bone and joint infection, Gram-positive bacteria, Infectious Diseases, Publications, tedizolid

Related Posts

Healthcare provider and health system leader perspectives on barriers to hypertension care in Malawi: insights from integrated and non-integrated HIV care settings

Hagstrom C, Kalande P, Aryal A, Phiri K, van Oosterhout JJ, Talama G, Lungu E, Phiri S, Moucheraud C, Hoffman R. Healthcare provider and health[...]

Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2–LTR Circles Over 12 Weeks

Reed JC, Hall L, McKhann A, Kwak G, Goecker EA, Coombs RW, Chen H, Roa J, Vecchio A, Daar ES, Hunt PW, Marra CM, Campbell[...]

Author Correction: Barcoded HIV-1 reveals viral persistence driven by clonal proliferation and distinct epigenetic patterns

Zhang TH, Shi Y, Komarova NL, Wodarz D, Kostelny M, Gonzales A, Abbaali I, Chen H, Bresson-Tan G, Dimapasoc M, Harvey W, Oh C, Carmona[...]